The human plasma and serum proteome

Proteomics of Human Body Fluids: Principles, Methods, and Applications

Volumn , Issue , 2007, Pages 195-224

  Omenn, Gilbert S ^a   Menon, Rajasree ^a   Adamski, Marcin ^a,b   Blackwell, Thomas ^a   Haab, Brian B ^c   Gao, Weimin ^d,e   States, David J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d Michigan Proteomics Alliance for Cancer Research   (United States)

^e TEXAS TECH UNIVERSITY   (United States)

Author keywords

abundance; complexity; dynamic range; error estimation; ex vivo modification; high throughput; Plasma proteome; posttranslational modifications; splice isoforms; variation

Indexed keywords

EID: 84920193812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-432-2_10     Document Type: Chapter

References (75)

1. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226-3245.
2. Also, Omenn GS. Exploring the Human Plasma Proteome. Wiley-Liss, 2006.
3. Ping P, Vondriska TM, Creighton CJ, et al. A functional annotation of subproteomes in human plasma. Proteomics 2005;5:3506-3519.
4. Putnam FW. The Plasma Proteins: Structure, Function, and Genetic Control. New York: Academic, 1975.
5. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1.11:845-867.
6. Echan LA, Tang H-Y, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high abundance proteins improves protein profiling capacities of human serum and plasma Proteomics 2005;5:3292-3303.
7. Rhodes DR, Tomlins SA, Varambally S, et al. Comprehensive model of the human protein-protein interaction network. Comput Biol 2005;8:1-9.
8. Peri S, Navarro JD, Amanchy R, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003;13:2363-2371.
9. Mann M, Aebersold R. Mass spectrometry-based proteomics. Nature 2003; 422;198-207.
10. Sadygov R, Yates JR. A hypergeometric probability model for protein identification and validation using tandem mass spectral data and protein sequence databases. Anal Chem 2003;75:3792-3798.
11. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383-5392.
12. Nesvizhskii AI, Keller A, Kolker E, et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646-4658.
13. Cargile BJ, Bundy JL, Stephenson JL, Jr. Potential for false positive identifications from large databases through tandem mass spectrometry. J Proteome Res 2004;3:1082-1085.
14. Kapp EA, Schutz F, Connolly LM, et al. An evaluation, comparison and accurate benchmarking of several publicly-available MS/MS search algorithms: Sensitivity and specificity analysis. Proteomics 2005;5:3475-3490.
15. Johnson RS, Davis MT, Taylor JA, Patterson SD. Informatics for protein identification by mass spectrometry. Methods 2005;35:223-236.
16. Marshall J, Kupchak P, Zhu W, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-372.
17. Rai AJ, Gelfand CA, Haywood BC, et al. Human Proteome Organization-Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 2005;5:3262-3277.
18. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-316.
19. Wang H, Clouthier SG, Galchev V, et al. Intact-protein based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005;4:618-625.
20. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-999.
21. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3:1154-1169.
22. Kuster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat Rev Mol Cell Biol 2005;6:577-583.
23. Craig R, Cortens UJP, Beavis RC. The use of proteotypic peptide libraries for protein identification. Rapid Commun Mass Spectrom 2005;19:1844-1850.
24. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005;1:252-262.
25. Haab B. Methods and applications of antibody microarrays in cancer research. Proteomics 2003;3:2116-2122.
26. Zhu H, Bilgin M, Bangham R, et al. Global analysis of protein activities using proteome chips. Science 2001;293:2101-2105.
27. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
28. Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of HUPO PPP reference specimens using SELDI-TOF mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005;5:3467-3474.
29. Pieper R, Gatlin CL, Makusky AJ, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003; 3:1345-1364.
30. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: Analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002;1:947-952.
31. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-1103.
32. Shen Y, Jacobs JM, Camp DG II, et al. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal Chem 2004;76:1134-1144.
33. Shen Y, Smith RD. Advanced nanoscale separations and mass spectrometry for sensitive high-throughput proteomics. Expert Rev Proteomics 2005;2:431-447.
34. Chan KC, Lucas DA, Hise D, et al. Analysis of the human serum proteome. Clin Proteomics 2004;1:101-226.
35. Zhou M, Lucas DA, Chan KC, et al. An investigation in the human serum interactome. Electrophoresis 2004;25:1289-1298.
36. Rose K, Bougueleret L, Baussant T, et al., Industrial-scale proteomics: From liters of plasma to chemically synthesized proteins. Proteomics 2004;4:2125-2150.
37. Hanash SM, Celis JE. The Human Proteome Organization: A mission to advance proteome knowledge. Mol Cell Proteomics 2002;1:413-414.
38. Omenn GS. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004;4:1235-1240.
39. Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, Apweiler, R. The International Protein Index: An integrated database for proteomics experiments. Proteomics 2004;4:1985-1988. http://www.ebi.ac.uk/IPI/IPIhelp.html.
40. Adamski M, States DJ, Omenn GS. Data standardization and integration in collaborative proteomics studies. In: Srivastava S, ed. Informatics in Proteomics. New York: Marcel Dekker, 2004:169-194.
41. Adamski M, Blackwell T, Menon R, et al. Data management and preliminary data analysis in the pilot phase of the HUPO Plasma Proteome Project. Proteomics 2005;5:3246-3261.
42. Carr S, Aebersold R, Baldwin M. The need for guidelines in publication of peptide and protein identification data. Mol Cell Proteomics 2004;3:351-353.
43. States DJ, Omenn GS, Blackwell TW, et al. Deriving high confidence protein identifications from a HUPO collaborative study of human serum and plasma. Nat Biotechnol 2006;24:333-338.
44. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-666.
45. Yang Z, Hancock WS, Richmond-Chew T, Bonilla L. A Study of glycoproteins in human serum and plasma reference standards (HUPO) using multi-lectin affinity chromatography coupled with RPLC-MS/MS. Proteomics 2005;5: 3353-3366.
46. Tang HY, Ali-Khan N, Echan LA, et al. A novel 4-dimensional strategy combining protein and peptide separation methods enables detection of low abundance proteins in human plasma and serum proteomes. Proteomics 2005;5:3329-3342.
47. Haab BB, Geierstanger BH, Michailidis G, et al. Immunoassay and antibody microarray analysis of the HUPO PPP reference specimens: Systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005;5:3278-3291.
48. Muthasamy B, Hanumanthu G, Reshmi R, et al. Plasma proteome database as a resource for proteomics research. Proteomics 2005;5:3531-3536.
49. Berhane BT, Zong C, Liem, et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005;5:3520-3530.
50. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-3422.
51. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-284.
52. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:226-230.
53. Uhlen M, Ponten F. Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 2005;4.4:384-393.
54. Hanash S. Harnessing immunity for disease proteomics. Nat Biotechnol 2003;21: 37-38.
55. Imafuku Y, Omenn GS, Hanash S. Proteomics approaches to identify auto-immune antibodies as cancer biomarkers. Dis Markers 2004;20:149-153.
56. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-1235.
57. Gao WM, Kuick R, Orchekowski RP, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005;5:110.
58. Hong SH, Misek DE, Wang H, et al. Auto-antibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004;64:5504-5510.
59. Ransohoff DF. Lessons from controversy: Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97:315-319.
60. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882-5890.
61. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-112.
62. Bouwman K, Qiu J, Zhou H, et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003;3:2200-2207.
63. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261-267.
64. Espina V, Woodhouse EC, Wulfkuhle J, et al. Protein microarray detection strategies: Focus on direct detection technologies. J Immunol Methods 2004;290: 121-133.
65. Barker PE, Wagner PD, Stein SE, Bunk DM, Srivastava S, Omenn GS. Standards for plasma and serum proteomics in early cancer detection: A needs assessment from the NIST-NCI SMART workshop. Clin Chem 2006;52:1669-1674.
66. Keller A, Purvine S, Nesvizhskii AI, Stolyar S, Goodlett DR, Kolker E. Experimental protein mixture for validating tandem mass spectral analysis OMICS. J Integr Biol 2002;6:207-212.
67. Strahler JR, Veine D, Walker A, et al. A publicly available dataset of MALDITOF/TOF and LTQ mass spectra of known proteins ASMS Session 2005: Bioinformatics Code: TP22 Time Slot/Poster Number: 398.
68. Nesvizhskii AI, Aebersold R. Interpretation of shotgun proteomic data-The protein inference problem. Mol Cell Proteomics 2005;4.10:1419-1440.
69. Rauch A, Bellew M, Eng J, et al. Computational Proteomics Analysis System (CPAS): An extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 2006;5:112-121.
70. Omenn GS. Strategies for proteomics profiling of human tumors. Proteomics 2006;6:5662-5673.
71. Adkins JN, Monroe ME, Auberry KJ, et al. A proteomic study of HUPO's Plasma Proteome Project pilot samples using an accurate mass and time tag strategy. Proteomics 2005;5:3454-3466.
72. Olsen JV, Mann M. Improved peptide identification in proteomics by two consecutive stages of mass spectrometric fragmentation. Proc Natl Acad Sci U S A 2004; 101:13, 417-13, 422.
73. Humphery-Smith I. A human proteome project with a beginning and an end. Proteomics 2004;4:2519-2521.
74. Aebersold R. Constellations in a cellular universe. Nature 2003;422:115-116.
75. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5(4):573-588.